Evotec Investor Presentation Deck

evotec Small molecules Biologics Cell and Gene therapy Multiple modalities²) PAGE 26 B EVOroyalty Building a robust, de-risked pipeline within EVOroyalty High-value partnerships offer path to increased royalties Pipeline assets in 2021 > 90 > 20 > 10 > 10 Number of projects¹) 49 2015 1) Excluding EVOequity 2) For these projects multiple modalities are currently being explored >130 2021 >170 2025 goal

View entire presentation